Plain-English translation of NCT07225712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see how well it works and how safe it is when taken daily for 52 weeks in adults with schizophrenia. You would start at a lower dose and gradually move to a standard dose, which your doctor would adjust based on how you respond. The study wants to understand whether this treatment helps control symptoms and is tolerable over the long term.
Schizophrenia is a serious mental health condition, and while there are treatments available, researchers are always looking for new options that may work better or have fewer side effects. This trial is designed to gather important safety and effectiveness information about this medication as a potential treatment option.
You likely qualify if…
You likely don't qualify if…
You would take the medication daily for 52 weeks, starting with a lower dose that gradually increases to a target dose. Your doctor will monitor you throughout the trial and may adjust your dose based on how you tolerate the medication and how you respond. You'll have regular check-ins and assessments to track your symptoms and any side effects.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
Japan
Phase
Large-scale testing
Sponsor
Otsuka Pharmaceutical Co., Ltd.
Enrollment target
~100 participants
Started
December 2025
Primary completion
March 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.